Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat - San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

Events

June 27, 2018

Marshelle Warren, Viracta’s Chief Medical Officer, will be presenting at the Gordon Research Conference, “New Perspectives on the Virus-Host Interplay in Nasopharyngeal Carcinoma and Their Impact on Diagnosis and Therapeutic Interventions,” in Hong Kong on June 27.

Recent News

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat - San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

Events

June 27, 2018

Marshelle Warren, Viracta’s Chief Medical Officer, will be presenting at the Gordon Research Conference, “New Perspectives on the Virus-Host Interplay in Nasopharyngeal Carcinoma and Their Impact on Diagnosis and Therapeutic Interventions,” in Hong Kong on June 27.